Loading…
Rhythm Pharmaceuticals, Inc. is projected to rise to $124.56 by 2027, a +18% move from its current price of $105.74. RYTM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/31/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 1 | $103.68 | $105.76 | $107.89 | +0.02% |
| Aug 2 | $102.85 | $105.79 | $108.81 | +0.04% |
| Aug 3 | $102.22 | $105.81 | $109.53 | +0.07% |
| Aug 4 | $101.70 | $105.83 | $110.14 | +0.09% |
| Aug 5 | $101.24 | $105.86 | $110.68 | +0.11% |
| Aug 6 | $100.83 | $105.88 | $111.18 | +0.13% |
| Aug 7 | $100.46 | $105.90 | $111.64 | +0.15% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $100.46 | $105.90 | $111.64 | +0.15% |
| Week 2 | $98.44 | $106.06 | $114.28 | +0.31% |
| Week 3 | $96.95 | $106.23 | $116.39 | +0.46% |
| Week 4 | $95.74 | $106.39 | $118.23 | +0.61% |
| Week 5 | $94.70 | $106.55 | $119.89 | +0.77% |
| Week 6 | $93.78 | $106.71 | $121.43 | +0.92% |
| Week 7 | $92.96 | $106.88 | $122.89 | +1.08% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focusing on the rare neuroendocrine diseases in the United States and internationally. Its lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity.
It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc.
and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Rhythm Pharmaceuticals, Inc. (RYTM) is currently priced at $106.09 per share and has a market capitalization of $7.28B. The company holds a mid-range ranking by market cap, listed as 1087.
A major floor 28.3% below — a decisive break under it would weaken the trend.
The nearest floor, 9.4% below — buyers have tended to step in here.
The nearest ceiling, 9.2% above — a clean break opens room to run.
A major ceiling 18.5% above — clearing it would confirm fresh momentum.
Key RYTM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RYTM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $105.71 | Buy | $105.93 | Sell |
| MA 10 | $105.30 | Buy | $106.07 | Sell |
| MA 20 | $108.24 | Sell | $105.88 | Sell |
| MA 50 | $99.73 | Buy | $101.74 | Buy |
| MA 100 | $93.51 | Buy | $98.40 | Buy |
| MA 200 | $99.03 | Buy | $94.95 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 51.46 | Neutral |
| Stoch RSI (14) | 40.91 | Neutral |
| CCI (20) | -51.55 | Neutral |
| Williams %R (14) | -53.69 | Info |
| MACD (12,26,9) | -0.81 | Sell |
| ROC (12) | -3.84 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 46.31 | Neutral |
| TRIX (15) | 0.28 | Buy |
| Awesome (5,34) | 0.48 | Buy |
| Ultimate (7,14,28) | 47.65 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -44.00 | Sell |
| Hull MA (9) | 107.28 | Sell |
| ADX (14) | 17.35 | Neutral |
| ATR (14) | 1.92 | Info |
The 30-day technical picture shows sentiment labeled as BULLISH, with RSI14 at 50. The 50-day simple moving average (SMA50) is $97.12 and the 200-day simple moving average (SMA200) is $98.75. Near-term support sits at $84.71 and resistance at $115.48. The 30-day range for the price runs from $91.26 to $123.33, and annualized volatility is 40%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.82 | $105.74 | $138.64 | 0% | Neutral | |
| $101.76 | $124.56 | $159.57 | +18% | Neutral | |
| $112.54 | $140.53 | $185.23 | +33% | Bullish | |
| $131.68 | $167.15 | $225.31 | +58% | Bullish | |
| $155.17 | $199.82 | $274.48 | +89% | Bullish | |
| $186.75 | $243.64 | $340.25 | +130% | Bullish | |
| $203.97 | $269.33 | $381.77 | +155% | Bullish | |
| $213.63 | $285.26 | $409.87 | +170% | Bullish | |
| $239.76 | $323.57 | $470.74 | +206% | Bullish | |
| $246.29 | $335.75 | $494.17 | +218% | Bullish | |
| $398.45 | $568.26 | $878.45 | +437% | Bullish | |
| $842.07 | $1,294.84 | $2,152.18 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $75.82 | $105.74 | $123.24 | +0.00% |
| August 2026 | $92.16 | $107.55 | $127.98 | +1.71% |
| September 2026 | $91.87 | $107.87 | $129.63 | +0.30% |
| October 2026 | $94.25 | $111.20 | $134.68 | +3.09% |
| November 2026 | $96.42 | $114.21 | $139.21 | +2.71% |
| December 2026 | $95.13 | $113.09 | $138.64 | -0.98% |
Click any year to see its month-by-month RYTM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The RYTM price prediction for 2026 points to an average of $105.74 (low $75.82, high $138.64) — a potential gain of 0% on today's $105.74. A consolidation phase looks the most probable path here.
In 2027, RYTM is projected to trade between $101.76 and $159.57, averaging $124.56 — a potential gain of +18% from today's $105.74. That is up +18% on the projected 2026 average. Price action looks broadly range-bound.
Rhythm Pharmaceuticals, Inc.'s 2028 outlook centres on $140.53, within a $112.54 to $185.23 range. That is up +13% on the projected 2027 average. That marks a +33% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, RYTM could reach as high as $225.31, with a base case around $167.15 and support toward $131.68 — roughly +58% from $105.74. Momentum favours further upside here.
Expect RYTM to range from $155.17 to $274.48 through 2030. The $199.82 average target implies a +89% move from current prices. That is up +20% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The RYTM price prediction for 2031 points to an average of $243.64 (low $186.75, high $340.25) — a potential gain of +130% on today's $105.74. Momentum favours further upside here.
In 2032, RYTM is projected to trade between $203.97 and $381.77, averaging $269.33 — a potential gain of +155% from today's $105.74. That is up +11% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Rhythm Pharmaceuticals, Inc.'s 2033 outlook centres on $285.26, within a $213.63 to $409.87 range. That is up +6% on the projected 2032 average. That marks a +170% change versus current levels. Momentum favours further upside here.
By 2034, RYTM could reach as high as $470.74, with a base case around $323.57 and support toward $239.76 — roughly +206% from $105.74. Buyers look set to stay in control over this stretch.
Expect RYTM to range from $246.29 to $494.17 through 2035. The $335.75 average target implies a +218% move from current prices. That is up +4% on the projected 2034 average. Momentum favours further upside here.
The RYTM price prediction for 2040 points to an average of $568.26 (low $398.45, high $878.45) — a potential gain of +437% on today's $105.74. Buyers look set to stay in control over this stretch.
In 2050, RYTM is projected to trade between $842.07 and $2,152.18, averaging $1,294.84 — a potential gain of +11.2x from today's $105.74. That is up +128% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in RYTM today (≈ 9.457159 RYTM) could be worth
$12,245.51
+$11,245.51 (+1125%) by 2050 · US Dollar
Based on the average projected RYTM price of $1,294.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RYTMwould be worth at today's price.
$1,000 invested in RYTM on Jul 30, 2025 (≈ 11.811953 RYTM) would be worth
$1,249
+$249 (+24.9%) today · 1.25× · US Dollar
Based on a RYTM entry price of $84.66 vs. today's $105.74.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $102.66 | $1,030 | +3.0% |
| 1 month ago | $111.03 | $952.36 | -4.8% |
| 3 months ago | $81.81 | $1,292.51 | +29.3% |
| 6 months ago | $102.52 | $1,031.41 | +3.1% |
| 1 year ago | $84.66 | $1,249 | +24.9% |
| All time (5.0y) ago | $17.42 | $6,070.03 | +507.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RYTM forecast.
Our base-case forecast reaches $210.00 around 2031.
Implied market cap at $210.00: $14.4B
Looking at the multi-year forecast, the yearly averages and ROIs show a progressive rise. For 2026 the avg is $106.09 with ROI 0 and sentiment NEUTRAL, then 2027 avg $124.17 with ROI 17.1 and NEUTRAL, 2028 avg $136.53 with ROI 28.7 and BULLISH, 2029 avg $160.06 with ROI 50.9 and BULLISH, 2030 avg $192.88 with ROI 81.8 and BULLISH, 2031 avg $229.59 with ROI 116.4 and BULLISH, 2032 avg $252.72 with ROI 138.2 and BULLISH, 2033 avg $269.99 with ROI 154.5 and BULLISH, 2034 avg $297.62 with ROI 180.5 and BULLISH, 2035 avg $305.96 with ROI 188.4 and BULLISH, 2040 avg $512.73 with ROI 383.3 and BULLISH, and 2050 avg $1,137.18 with ROI 971.9 and BULLISH. These figures imply a strong long-term upside despite the uncertainty inherent in forecasts.
In 2040 the avg is $512.73 and in 2050 the avg is $1,137.18, with max values $821.78 and $1,973.95 respectively. These are estimates, not guarantees, and actual results will depend on market conditions and company performance.
Tap a question to reveal the answer.
In 2030 the forecasted avg price is $192.88, with a min of $147.06 and a max of $271.16, and a projected ROI of 81.8% with sentiment BULLISH.
Forecasts show bullish sentiment from 2027 onward with rising averages and ROIs, including 2040 avg $512.73 (ROI 383.3) and 2050 avg $1,137.18 (ROI 971.9). The 2026 figure shows an avg of $106.09 with ROI 0 and NEUTRAL sentiment. These are estimates, not guarantees.
Yes. The 2030 forecast lists a max of $271.16, with an average of $192.88 and a min of $147.06, and ROI of 81.8% with a BULLISH sentiment.
The current price is $106.09 and the market capitalization is $7.28B.
For 2040 the forecast shows an average of $512.73, a min of $346.76, and a max of $821.78, with ROI of 383.3 and sentiment BULLISH.
Rhythm Pharmaceuticals, Inc. Community Discussion
0Share your Rhythm Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.